Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].

Core Insights - UnitedHealth Group Inc (NYSE:UNH) has experienced a significant decline of 39.1% year-to-date in 2025, primarily due to rising medical costs and the unexpected departure of CEO Andrew Witty [1] - Despite the challenges, options trading activity remains robust, with a notable volume of both calls and puts in recent trading sessions [2] Options Trading Activity - Over the last 10 trading days, UnitedHealth recorded a total of 4,843,914 options, comprising 3,313,688 calls and 1,530,226 puts [2][3] - The most popular options contract was the weekly 5/23 300-strike call, indicating strong interest among traders [2] Stock Performance - UnitedHealth shares were last observed at $307.50, reflecting a 1.9% increase and marking a potential fourth consecutive daily gain [5] - The stock is attempting to recover from a significant dip to $269.13 on May 16, which was its lowest level since April 2020 [5] Volatility Metrics - The Schaeffer's Volatility Scorecard (SVS) for UnitedHealth ranks at 95 out of 100, suggesting that the stock typically exceeds options traders' annual volatility expectations [7]

Core Insights - UnitedHealth Group Incorporated (UNH) shares have dropped 25.4% in the past month, resulting in a year-to-date loss of 40.4%, significantly underperforming both the broader industry and the S&P 500 [1][7] - The company is facing multiple pressures, including rising medical costs, missed earnings and revenue estimates, and a withdrawal of its 2025 financial guidance [4][15] - Investor sentiment is deteriorating, with numerous downward revisions to earnings estimates for 2025 and 2026, despite projected revenue growth [7][8] Financial Performance - UnitedHealth generated $5.5 billion in operating cash flow in the first quarter, a substantial increase from $1.1 billion the previous year, and ended the quarter with $34.3 billion in cash and short-term investments [14] - The Zacks Consensus Estimate for UNH's 2025 EPS has seen 12 downward revisions, projecting a decline of 17.3%, while revenues are expected to increase by 12.9% year over year [7][8] Market Position and Valuation - UNH is trading at a forward P/E of 12.31X, below its five-year median of 19.20X but above the industry average of 11.50X, indicating a mixed valuation perspective [8][10] - Despite appearing attractively priced, regulatory risks, cost pressures, and reputational damage pose significant threats to the company's business model [10][15] Competitive Advantages - UnitedHealth retains competitive advantages through its vertically integrated model, scale, and investments in AI and digital health, which may help navigate long-term industry trends [12] - The company served 50.1 million members as of March 31, 2025, reflecting a 1.9% year-over-year growth, driven by self-funded commercial plans [13] Outlook and Recommendations - The near-term outlook for UnitedHealth is clouded by setbacks, including regulatory probes and leadership changes, which have undermined investor confidence [15][16] - With no clear catalysts for recovery and significant underperformance, it may be prudent for investors to wait for signs of stabilization before re-entering [16]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including administering Medicaid benefits, which were affected by a federal pause on eligibility reviews during COVID-19 [3]. - Following the end of the pause in 2023, states resumed redetermining Medicaid eligibility, which led to significant increases in acuity and utilization among Elevance's Medicaid members [5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate [4]. - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, causing a further stock decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - A class action securities lawsuit has been filed against UnitedHealth Group Incorporated, alleging securities fraud that adversely affected investors between December 3, 2024, and April 16, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further damaged the company's reputation [3]. - Following the murder, there was significant animosity towards UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [3]. - Despite the backlash, UnitedHealth continued to adhere to its previous guidance, which was deemed unrealistic given the changing corporate strategies [3]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until July 7, 2025, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in UnitedHealth Group Incorporated ("UnitedHealth Group Incorporated" or the "Company") (NYSE: UNH) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of UnitedHealth Group Incorporated investors who were adversely affected by alleged securities fraud between December 3, 2024 and April 16, 2025. Follow the link below to get more information and be contacted by a member of our tea ...

Group 1 - The Portnoy Law Firm is advising investors of UnitedHealth Group Incorporated regarding a class action for securities purchased between December 3, 2024, and April 16, 2025, with a deadline for filing a lead plaintiff motion by July 7, 2025 [1] - A criminal investigation by the U.S. Department of Justice into UnitedHealth Group is ongoing, focusing on potential Medicare fraud related to the company's Medicare Advantage business practices, which has been under investigation since at least summer 2024 [3] - UnitedHealth announced on May 13, 2025, that it was withdrawing its previously revised financial guidance from April 17, 2025, and disclosed a leadership change with CEO Andrew Witty stepping down and being succeeded by Chairman Stephen Hemsley [4]

Core Viewpoint - UnitedHealth Group is facing significant scrutiny and legal challenges following allegations of undisclosed payments to nursing homes aimed at reducing hospital transfers, which has led to concerns about patient care and corporate practices [1][3][4]. Group 1: Allegations and Legal Issues - Allegations have emerged that UnitedHealth incentivized nursing facilities to limit hospitalizations among Medicare Advantage enrollees, potentially compromising patient care [3][4]. - The company is currently involved in a securities fraud class action lawsuit, with claims that it improperly denied health coverage to enhance profits, leading to regulatory scrutiny [5][6]. - A significant drop in UnitedHealth's stock price occurred after the company reduced its financial guidance for 2025, attributing it to unexpected increases in care activity within its Medicare Advantage business [6][7]. Group 2: Management and Regulatory Scrutiny - The abrupt departure of CEO Andrew Witty on May 13, 2025, has added to the turmoil within the company, resulting in a more than 10% decline in share price on that day [7]. - Federal authorities are investigating whether UnitedHealth engaged in "upcoding," a practice that could inflate Medicare payments by misrepresenting patient diagnoses [8]. Group 3: Investigations and Responses - Hagens Berman, a law firm, is investigating the securities fraud claims against UnitedHealth and is encouraging investors who have suffered losses to come forward [2][9]. - The firm has raised concerns about the implications of the recent allegations on UnitedHealth's commitment to patient care and transparency [10].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of UnitedHealth Group Incorporated regarding a class action lawsuit due to allegations of misleading statements and corporate misconduct during a specified class period [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that UnitedHealth engaged in a corporate strategy of denying health coverage to increase profits and share price [3]. - This strategy led to regulatory scrutiny and public outrage, culminating in the murder of Brian Thompson, which further fueled animosity towards the company [3]. - Following the murder, there was significant public backlash against UnitedHealth, with many Americans expressing support for the accused killer and demanding changes in the company's practices [3]. - Despite the changing corporate environment, UnitedHealth continued to adhere to its previous guidance, which was deemed unrealistic [3]. - The allegations assert that the defendants' public statements were materially false and misleading throughout the relevant period [3]. Class Action Details - The class period for the lawsuit is defined as December 3, 2024, to April 16, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of July 7, 2025, to potentially become lead plaintiffs [4]. - Registration allows shareholders to receive updates on the case's progress through a portfolio monitoring software [4]. Firm Background - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. The EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].